CD8A and neoplasm: Quantification of (A) CD8+ T cells, (B) Ki-67+ CD8+ T cells and (C) Eomes+ CD8+ T cells in the lungs of tumor bearing CCSP-rtTA; TetO-EGFRL858R mice in the absence (−) and presence (+) of erlotinib, CD40 agonist or erlotinib plus the CD40 agonist for 2 weeks, (n = 4–6 mice per group).